Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats

Journal of Physiology and Biochemistry

Volumn 72, Issue 3, 2016, Pages 555-566

  Llarena, Marta ^a   Andrade, Fernando ^a   Hasnaoui, Mounia ^b   Portillo, María P ^a   Pérez Matute, Patricia ^c   Arbones Mainar, Jose M ^a   Hijona, Elizabeth ^d   Villanueva Millán, María Jesús ^c   Aguirre, Leixuri ^a   Carpéné, Christian ^b   Aldámiz Echevarría, Luis ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSERM   (France)

^c CENTER FOR BIOMEDICAL RESEARCH OF LA RIOJA CIBIR   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Nephropathy; Obesity complications; Piceatannol; Renoprotection; Resveratrol analogue; Zucker rats

Indexed keywords

3 NITROTYROSINE; CREATININE; FIBRONECTIN; KIDNEY INJURY MOLECULE 1; OMEGA 6 FATTY ACID; PICEATANNOL; POLYUNSATURATED FATTY ACID; SIRTUIN 1; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1; 3,3',4,5'-TETRAHYDROXYSTILBENE; 3-NITROTYROSINE; ANTIOXIDANT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; HAVCR1PROTEIN, RAT; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; KIDNEY DISEASE; KIDNEY FIBROSIS; LIPID PEROXIDATION; MALE; NITROSATIVE STRESS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEINURIA; RAT; RENAL PROTECTION; ZUCKER RAT; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DIET THERAPY; DIETARY SUPPLEMENT; FIBROSIS; IMMUNOLOGY; KIDNEY; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; URINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BIOMARKERS; CELL ADHESION MOLECULES; DIETARY SUPPLEMENTS; FIBROSIS; KIDNEY; LIPID PEROXIDATION; MALE; OBESITY; ORGAN SIZE; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS, ZUCKER; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; STILBENES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TYROSINE;

EID: 84949544702     PISSN: 11387548     EISSN: 18778755     Source Type: Journal    
DOI: 10.1007/s13105-015-0457-1     Document Type: Article

References (51)

1. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB (2002) Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation. J Immunol 169:6490–6497
2. Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV (2002) Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 277(42):39739–39748
3. Bavaresco L (2003) Role of viticultural factors on stilbene concentrations of grapes and wine. Drugs Exp Clin Res 29:181–187
4. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74:619–624
5. Biesalski HK (2007) Polyphenols and inflammation: basic interactions. Curr Opin Clin Nutr Metab Care 10(6):724–728
6. Chander PN, Gealekman O, Brodsky SV, Elitok S, Tojo A, Crabtree M, Gross SS, Goligorsky MS (2004) Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 15:2391–2403
7. Chanvitayapongs S, Draczynska-Lusiak B, Sun AY (1997) Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport 8(6):1499–1502
8. Chen KH, Hung CC, Hsu HH, Jing YH, Yang CW, Chen JK (2011) Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chem Biol Interact 190(1):45–53
9. Chiusolo A, Defazio R, Zanetti E, Mongillo M, Mori N, Cristofori P, Trevisan A (2010) Kidney injury molecule-1 expression in rat proximal tubule after treatment with segment-specific nephrotoxicants: a tool for early screening of potential kidney toxicity. Toxicol Pathol 38(3):338–345
10. Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57(1):167–182
11. Dronavalli S, Duka I, Bakris GL (2008) The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4(8):444–452
12. Goknar N, Oktem F, Ozgen IT, Torun E, Kucukkoc M, Demir AD, Cesur Y (2015) Determination of early urinary renal injury markers in obese children. Pediatr Nephrol 30(1):139–144
13. Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L, Milagro F, Martínez JA, Portillo MP (2012) Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr 107(2):202–210
14. Hosohata K, Ando H, Takeshita Y, Misu H, Takamura T, Kaneko S, Fujimura A (2014) Urinary Kim-1 is a sensitive biomarker for the early stage of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Diab Vasc Dis Res 11(4):243–250
15. Hussein JS (2013) Cell membrane fatty acids and health. Int J Pharm Pharm Sci 5(3):38–46
16. Iliescu R, Chade AR (2010) Progressive renal vascular proliferation and injury in obese Zucker rats. Microcirculation 17(4):250–8
17. Kasiske BL, O’Donnell MP, Keane WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19:I110–115
18. Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, Park SK, Han MK, Lee SY, Ramkumar KM, Sung MJ, Kim W (2011) Sirt1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol 301(2):F427–435
19. Kitada M, Koya D (2013) Renal protective effects of resveratrol. Oxid Med Cell Longev 2013:568093
20. Kitada M, Kume S, Imaizumi N, Koya D (2011) Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1- independent pathway. Diabetes 60(2):634–643
21. Kitada M, Kume S, Takeda-Watanabe A, Kanasaki K, Koya D (2013) Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 124(3):153–164
22. Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D (2011) Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res 2011:908185
23. Kopelman PG (2000) Obesity as a medical problem. Nature 404:635–643
24. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS (1996) Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74(6):991–1003
25. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127(6):1109–1122
26. Laping NJ, Olson BA, Day JR, Brickson BM, Contino LC, Short BG, Ali SM, Brooks DP (1998) The age-related increase in renal clusterin mRNA is accelerated in obese Zucker rats. J Am Soc Nephrol 9:38–45
27. Lee GT, Ha H, Jung M, Li H, Hong SW, Cha BS, Lee HC, Cho YD (2003) Delayed treatment with lithospermate B attenuates experimental diabetic renal injury. J Am Soc Nephrol 14(3):709–720
28. Leonard SS, Xia C, Jiang B-H, Stinefelt B, Klandorf H, Harris GK, Shi X (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309(4):1017–1026
29. Lepage G, Roy CC (1986) Direct transesterification of all classes of lipids in one-step reaction. J Lip Res 27:114–120
30. Loke WM, Proudfoot JM, Hodgson JM, McKinley AJ, Hime N, Magat M, Stocker R, Croft KD (2010) Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction. Arterioscler Thromb Vasc Biol 30(4):749–757
31. Lu T, Harper AF, Zhao J, Corl BA, LeRoith T, Dalloul RA (2014) Effects of a dietary antioxidant blend and vitamin E on fatty acid profile, liver function, and inflammatory response in broiler chickens fed a diet high in oxidants. Poult Sci 93(7):1658–1666
32. Malar DS, Devi KP (2014) Dietary polyphenols for treatment of Alzheimer’s disease—future research and development. Curr Pharm Biotechnol 15(4):330–342
33. Murakami A, Ashida H, Terao J (2008) Multitargeted cancer prevention by quercetin. Cancer Lett 269(2):315–325
34. Murias M, Jäger W, Handler N, Erker T, Horvath Z, Szekeres T, Nohl H, Gille L (2005) Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 69(6):903–912
35. Paczek L, Teschner M, Schaefer RM, Heidland A (1991) Intraglomerular fibronectin accumulation and degradation in obese Zucker rats. Diabetologia 34(11):786–789
36. Palsamy P, Subramanian S (2011) Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta 1812(7):719–731
37. Piotrowska H, Kucinska M, Murias M (2012) Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res 750:60–82
38. Poirier B, Lannaud-Bournoville M, Conti M, Bazin R, Michel O, Bariéty J, Chevalier J, Myara I (2000) Oxidative stress occurs in absence of hyperglycaemia and inflammation in the onset of kidney lesions in normotensive obese rats. Nephrol Dial Transplant 15:467–476
39. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR (2004) Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem 52:4713–4719
40. Ruiz JI, Ochoa B (1997) Quantification in the subnanomolar range of phospholipids and neutral lipids by monodimensional thin-layer chromatography and image analysis. J Lipid Res 38:1482–1489
41. Setoguchi Y, Oritani Y, Ito R, Inagaki H, Maruki-Uchida H, Ichiyanagi T, Ito T (2014) Absorption and metabolism of piceatannol in rats. J Agric Food Chem 62(12):2541–2548
42. Shaikh SR, Edidin M (2006) Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation. Am J Clin Nutr 84(6):1277–1289
43. Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K (2006) Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 76(2):69–75
44. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ (1999) Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 34(5):818–823
45. Slyvka Y, Inman SR, Malgor R, Jackson EJ, Yee J, Oshogwemoh O, Adame J, Nowak FV (2009) Protective effects of antioxidant-fortified diet on renal function and metabolic profile in obese Zucker rat. Endocrine 35(1):89–100
46. Son PS, Park SA, Na HK, Jue DM, Kim S, Surh YJ (2010) Piceatannol, a catechol-type polyphenol, inhibits phorbol ester-induced NF-κB activation and cyclooxygenase-2 expression in human breast epithelial cells: cysteine 179 of IKKβ as a potential target. Carcinogenesis 31(8):1442–1449
47. van Timmeren MM, Bakker SJ, Vaidya VS, Bailly V, Schuurs TA, Damman J, Stegeman CA, Bonventre JV, van Goor H (2006) Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol 291(2):F456–464
48. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA (2007) Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 212:209–217
49. Wu L, Zhang Y, Ma X, Zhang N, Qin G (2012) The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol Biol Rep 39(9):9085–9093
50. Zhang Q, Davis KJ, Hoffmann D, Vaidya VS, Brown RP, Goering PL (2014) Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats. Biomark Med 8(1):85–94
51. Ziyadeh FN, Han DC (1997) Involvement of transforming growth factor-beta and its receptors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl 60:S7–11